Skip to content

Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System

Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07139808
Enrollment
12
Registered
2025-08-24
Start date
2025-08-01
Completion date
2026-12-01
Last updated
2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type1diabetes

Brief summary

The study is to evaluate the accuracy and safety of a novel real-time continuous glucose and ketone monitoring system among adult patients with type 1 diabetes mellitus (T1DM) with respect to Yellow Spring Instrument (YSI) and Randox reference venous plasma sample measurements.

Detailed description

The study is to evaluate the accuracy and safety of a novel real-time continuous glucose and ketone monitoring (CGKM) system among adult patients with type 1 diabetes mellitus with respect to YSI and Randox reference venous plasma sample measurements. Up to 14 patients will be enrolled. Interstitial glucose and ketone readings from the sensors will be obtained immediatedly following each venous blood sample test. Each participant will make 3 visits to the clinical study site, including the screening visit.

Interventions

DEVICEGK5 CGKM

Wear for a consecutive 15 days

Sponsors

Henan University of Science and Technology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Diagonsed with T1DM on Continuous subcutaneous insulin infusion (CSII) * Venous blood sampling access can be established in the forearm * Capable of independently reading instructions and complying with the clinical trial requirements * Willing to sign the Informed Consent Form (ICF)

Exclusion criteria

* Severe hypoglycemia within the past 6 months * A diagnosed history of Diabetic ketoacidosis (DKA) in the past 3 months * Heart failure or hemiplegic sequelae due to prior cerebrovascular disease * Severe skin conditions at the sensor wear site * Extensive systemic skin disorders * Having difficulty with wound healing, bleeding disorders, and/or taking anticoagulant medications * Anemia or abnormal hematocrit * Blood donation within the past 6 months * Pregnancy (defined as positive urine test in women ≤55 years), lactation, or plans for pregnancy within ≤30 days * Current or recent (≤1 month) participation in other clinical trials * Planned MRI/CT scans during sensor wear * Allergy to medical adhesives or alcohol * Conditions impairing comprehension of informed consent or study procedures * Other exclusionary conditions per investigator's discretion

Design outcomes

Primary

MeasureTime frameDescription
System performance on glucose measurement15 daysThe CGK system performance for glucose measurement will be assessed by comparing to the Yellow Springs Instrument comparator venous plasma measurements
System performance on ketone measurement15 daysThe CGK system performance for ketone measurement will be assessed by comparing to the Randox comparator venous plasma measurements

Secondary

MeasureTime frameDescription
System-related Safety15 daysRecords of the adverse events and device-related incidence rates.

Countries

China

Contacts

CONTACTPeng Liu
peng.liu87@outlook.com0379-64811993
PRINCIPAL_INVESTIGATORHongwei Jiang

Henan University of Science and Technology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 12, 2026